Cost Effectiveness Of Sunitinib In Central America And Caribbean
Status:
Terminated
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
Primary Hypothesis: The therapy with Sunitinib represents better cost-effectiveness than
IFN-α in first-line treatment for metastatic Renal Cell Carcinoma (mRCC) in Central America
and Caribbean countries